KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Research & Development (2016 - 2025)

Sarepta Therapeutics has reported Research & Development over the past 15 years, most recently at $325.3 million for Q4 2025.

  • For Q4 2025, Research & Development rose 62.71% year-over-year to $325.3 million; the TTM value through Dec 2025 reached $1.5 billion, up 89.19%, while the annual FY2025 figure was $1.5 billion, 89.19% up from the prior year.
  • Research & Development for Q4 2025 was $325.3 million at Sarepta Therapeutics, up from $218.9 million in the prior quarter.
  • Over five years, Research & Development peaked at $773.4 million in Q1 2025 and troughed at $139.1 million in Q3 2021.
  • A 5-year average of $242.6 million and a median of $209.1 million in 2022 define the central range for Research & Development.
  • Biggest five-year swings in Research & Development: fell 26.95% in 2021 and later surged 285.96% in 2025.
  • Year by year, Research & Development stood at $197.3 million in 2021, then rose by 8.37% to $213.8 million in 2022, then dropped by 8.55% to $195.5 million in 2023, then increased by 2.27% to $200.0 million in 2024, then soared by 62.71% to $325.3 million in 2025.
  • Business Quant data shows Research & Development for SRPT at $325.3 million in Q4 2025, $218.9 million in Q3 2025, and $204.4 million in Q2 2025.